All In MedTech

FDA Clearance Tracker · P120005-S042

DEXCOM G4 PLATINUM CONTINUOUS GLUCOSE MONITORING SYSTEM,DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 5, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 5, 2016

Approved

Time to decision

73 days

Received Nov 24, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P120005-S042
Device name
DEXCOM G4 PLATINUM CONTINUOUS GLUCOSE MONITORING SYSTEM,DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Nov 24, 2015
Decided
Feb 5, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P120005

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

Approval for modifications to the attachment method that secures the disposable housing to the adhesive patch of the sensor pod of the G4 PLATINUM/G5 Mobile sensor component which required modifications to the disposable housing, implementation of a semi-automated heat staking machine and a change to the inspection method. The proposed change occurs at Tech Group, Dexcom’s approved supplier. The sensor is a component of the Dexcom G4 Platinum and Dexcom G5 Mobile Continuous Glucose Monitoring Systems.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.